• Milk-Derived Vesicle Uptake in Intestinal Organoids

  2026-10-01

  This study develops three porcine intestinal stem cell–based models to examine milk-derived extracellular vesicle uptake in physiologically relevant epithelium. Its central findings are that uptake depends on epithelial polarity, differs among organoid formats, and is sensitive to endocytosis inhibition, while colon-derived models show transcriptional responses associated with stemness and differentiation.

• Neticonazole Hydrochloride: Dual-Use Workflows

  2026-10-01

  Neticonazole Hydrochloride supports two distinct research workflows: fungal growth control through membrane-synthesis disruption and exploratory colorectal cancer research focused on exosome release and apoptosis. This guide translates those activities into practical assay design, formulation handling, and troubleshooting decisions while separating established topical use from preclinical oncology evidence.

• Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT

  2026-09-30

  This 2024 Journal of Ethnopharmacology study combines network pharmacology with cellular and mouse experiments to examine how Shenqi Fuzheng injection affects glioma proliferation and migration. Its results implicate SRC/PI3K/AKT signaling, cell-cycle arrest, and epithelial–mesenchymal transition changes, while also showing why these findings remain mechanistic and preclinical rather than clinical proof.

• Chronic Cabozantinib Adaptation in RCC

  2026-09-30

  This study uses quantitative phosphoproteomics to distinguish acute kinase-pathway suppression from chronic signaling adaptation during Cabozantinib exposure in renal cell carcinoma. Its central finding is that prolonged treatment preserves suppression of MET activation-loop phosphorylation while selectively remodeling adhesion- and MAPK-associated networks linked to modest, pattern-specific changes in cellular motility.

• FLT3–TAZ Signaling Drives Drug Resistance in BP-CML

  2026-09-29

  Shin et al. repositioned FLT3 as both a prognostic marker and therapeutic vulnerability in blast-phase chronic myeloid leukemia (BP-CML). Their data connect FLT3 to a JAK–STAT3–TAZ–TEAD–CD36 circuit that promotes resistance to BCR::ABL1 tyrosine kinase inhibitors, while supporting FLT3-directed combinations and ponatinib-based treatment strategies in preclinical models.

• Sorafenib: A Mechanism-to-Assay Research Guide

  2026-09-29

  Sorafenib and BAY-43-9006 connect RAF signaling, VEGFR-2 blockade, and tumor angiogenesis in one versatile cancer biology research tool. This guide translates kinase pharmacology and recent VEGFR-2 inhibitor findings into better assay design, model selection, and data interpretation.

• Auranofin: TrxR Inhibitor for Redox Research

  2026-09-28

  Auranofin is a thioredoxin reductase inhibitor that disrupts cellular redox control and supports apoptosis-focused cancer research. Product-reported benchmarks include nanomolar TrxR inhibition, suppression of Helicobacter pylori growth, and radiosensitization of murine tumor cells under defined experimental conditions.

• BFH772 (VEGFR2 inhibitor): Practical Workflow

  2026-09-28

  BFH772 is a small-molecule VEGFR2 inhibitor for research workflows examining VEGFR2-associated signaling and angiogenesis, including tumor angiogenesis models. Its water insolubility and defined kinase selectivity make it a poor fit for aqueous stock preparation or experiments that require broad-spectrum kinase inhibition.

• CCK-8 Reduces Anxiety-Like Behavior in Morphine Withdrawal

  2026-09-27

  Wen and colleagues found that cholecystokinin octapeptide (CCK-8) reduced anxiety-like behavior in morphine-withdrawal rats, with pharmacological blockade implicating CCK1 receptors and endogenous μ-opioid signaling. The findings identify a receptor-mediated interaction relevant to withdrawal-related affect, while leaving the underlying opioid release mechanism and clinical applicability unresolved.

• Cabozantinib in RCC: Reading Adaptation Over Time

  2026-09-26

  Cabozantinib (XL184) can suppress kinase signaling yet leave room for time-dependent cellular adaptation. This article explains how to interpret phosphoproteomic and motility findings in renal cell carcinoma models—and how they can guide more informative experiments.

• Dovitinib: From RTK Inhibition to Translational Insight

  2026-09-25

  Dovitinib (TKI-258, CHIR-258) offers a way to interrogate interconnected receptor tyrosine kinase signaling and apoptosis in cancer models. This article frames its broad activity as an experimental advantage—and a challenge—then outlines how to build more informative, translationally relevant studies.

• Berberine Hydrochloride in Metabolic Research

  2026-09-25

  Use Berberine hydrochloride to build controlled cell-based studies of AMPK-linked metabolic regulation, LDLR expression, and context-dependent cell-death readouts. This guide combines a practical solubility and dosing workflow with a careful comparison to recent oxidized-DNA research in acute kidney injury—without assuming the mechanisms are interchangeable.

• Meropenem Trihydrate in Resistance Research

  2026-09-24

  Use Meropenem trihydrate to connect isolate-level susceptibility testing with metabolomic studies of carbapenem resistance. A paired antibiotic-free and drug-exposed workflow helps distinguish baseline resistance-associated signatures from short-term responses to cell-wall stress.

• Live-Dead Cell Staining Kit for Viability Workflows

  2026-09-24

  Pairing Calcein-AM with Propidium Iodide separates cells with intact membranes and esterase activity from membrane-compromised cells in one readout. This guide applies the Live-Dead Cell Staining Kit to microscopy, flow cytometry, and biomaterial or drug cytotoxicity workflows, with practical controls and optimization steps.

• 25-Hydroxycholesterol Reprograms Immunosuppressive TAMs

  2026-09-23

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic signal that activates lysosomal AMPKα and reinforces STAT6-dependent ARG1 production in tumor-associated macrophages. Their findings connect macrophage cholesterol metabolism with T-cell suppression and show that targeting CH25H can improve antitumor responses, including in combination with anti-PD-1 therapy.

8129 records 1/542 page Next 12345 下5页 Last page